Association between SGLT2 Inhibitors vs DPP-4 Inhibitors and Risk of Pneumonia Among Patients with Type 2 Diabetes.
Philip C M AuKathryn C B TanBernard M Y CheungIan C K WongYing WongChing-Lung CheungPublished in: The Journal of clinical endocrinology and metabolism (2021)
Compared to DPP4is, SGLT2is use was associated with a reduced risk of pneumonia and pneumonia mortality in a real-world setting.